A systematic review and meta-analysis of *Toxoplasma gondii* infection among the Mexican population

Ma de la Luz Galvan-Ramirez¹*, Rogelio Troyo¹, Sonia Roman³, Carlos Calvillo-Sanchez¹ and Rosamaria Bernal-Redondo²

**Abstract**

**Background:** Toxoplasmosis is a disease caused by *Toxoplasma gondii* and at least one-third of the world’s population has detectable *T. gondii* antibodies. The seroprevalence of *T.gondii* ranges from 15% to 50% among the Mexican general population. The aim of this work was to determine the mean prevalence and weighted mean prevalence of *T. gondii* infection, and to evaluate the epidemiological transition of infection in Mexico.

**Methods:** Pub Med, Lilacs, Medline, Latindex, Google Scholar data bases were searched to retrieve reports from 1951 up to 2012 regarding prevalence data, diagnostic tests and risk factors of infection among the adult population. Data collection and criteria eligibility was established in order to determine the crude prevalence (proportion of positive cases) of each study, together with weighted population prevalence according to individual research group categories to limit the bias that may impose the heterogeneous nature of the reports. A Forest Plot chart and linear regression analysis were performed by plotting the prevalence of infection reported from each study over a period of sixty years.

**Results:** A total of 132 studies were collected from 41 publications that included 70,123 individuals. The average mean prevalence was 27.97%, and weighted mean prevalence was 19.27%. Comparisons among different risk groups showed that the weighted prevalence was higher in women with miscarriages (36.03%), immunocompromised patients (28.54%), mentally-ill patients (38.52%) and other risk groups (35.13%). *Toxoplasma* infection among the Mexican population showed a downward trend of 0.1%/year over a period of sixty years that represents a 5.8% reduction in prevalence.

**Conclusions:** This analysis showed a downward trend of infection; however, there are individuals at high risk for infection such as immunocompromised patients, mentally-ill patients and pregnant women. Further research is required to provide better prevention strategies, effective diagnostic testing and medical management of patients. Educational efforts are required to avoid the transmission of infection in populations that cannot be controlled by drugs alone.

**Keywords:** Toxoplasmosis, *Toxoplasma* infection, Mexican population, Epidemiology, Meta-analysis

* Correspondence: mlgalvanr@gmail.com

¹Department of Physiology, Neurophysiology Laboratory, Health Sciences University Center, University of Guadalajara, Sierra Mojada # 950 Edificio N, Col. Independencia, Guadalajara, Jalisco 44320, México

Full list of author information is available at the end of the article

© 2012 Galvan-Ramirez et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Toxoplasmosis is a disease caused by *Toxoplasma gondii* (*T. gondii*). It was described in a North African rodent (*Cteionodactylus gondii*) by Nicolle and Manceaux in 1908 [1]. The *T. gondii* is an obligate intracellular parasite with a complex life cycle, in which homeothermic animals, including humans are capable of acting as intermediate hosts. Humans acquire the parasite by the oral route through the consumption of undercooked meat contaminated with cysts, food products (vegetables and fruits) or water contaminated with oocysts [1,2]. Other routes of transmission are organ transplantation [3,4], blood transfusion [5] and congenital transmission. Butchers, slaughterhouse workers and laboratory personnel that handle cultures and animal models with this parasite are also at risk. However, for the majority of the human population, transmission generally occurs by any of the routes aforementioned [6].

*T. gondii* is found worldwide because a large variety of animals may harbor the parasite and maintain its dissemination. Its broad geographic location is related to several factors, such as contact with infected cat feces and ingestion of mature oocysts [7], food habits and variations in climate. The later has a significant influence on the habitat of *T. gondii*; for instance, an increase in ambient temperature and precipitation can change the humidity of the soil, so that the sporulated oocysts remain viable in the moist environment for a longer period [8,9].

*T. gondii* is considered as the most prevalent parasitic zoonotic disease worldwide [10], since at least one-third of the world's population is infected [11]. Infections caused by *T. gondii* are more frequent in temperate zones than in cold ones; thus, France has the highest prevalence of 90%, whereas the lowest prevalence is found in Alaska with only 1%. However, global warming has caused an increase of *T. gondii* infections in different regions of the world as a result of changing environmental conditions [8].

The mean prevalence of *T. gondii* infection among the Mexican general population is 50%; however, there are variations that depend on climate and humidity. Several risk groups have been identified with high prevalence of infection such as cat owners, people who consume raw or undercooked meat, immunocompromised patients and those that undergo organ transplantation [3,4]. Furthermore, we recently carried out a meta-analysis on reports of toxoplasmosis among Mexican newborns. The weighted prevalence in 4833 asymptomatic newborns was 0.616%, whereas, among 895 symptomatic newborns, the weighed prevalence was 3.02% [12].

Diagnostic testing for toxoplasmosis can be done by staining body fluids or mouse inoculation to see if Toxoplasma parasites develop. Skin test antigen (toxoplasmin) (STA), and serological procedures such as the Complement Fixation Test (CF), Latex Flocculation Test (LF), Sabin and Feldman (SF), Indirect Haemagglutination Test (IHA), Indirect Immunofluorescence assay (IFI), and Enzyme-linked immunosorbent assay (ELISA) have been employed to detect specific antibodies in screening programs and also as adjuncts to the diagnosis of acute toxoplasmosis. More recently other methods have been developed such as Western-blot and detection of DNA with polymerase chain reaction (PCR) [1,4].

Treatment for human toxoplasmosis is highly important for immunocompromised patients or acutely infected pregnant women. Various pharmacological agents are available such as pyrimethamine alone or combined with sulfadiazone. Atovaquone has been used as a second course of treatment for retinocchoroiditis. Azithromycin is used as an alternative in the treatment of ocular and cerebral toxoplasmosis in AIDS patients, as well as, for active, non-vision-threatening toxoplastic retinocchoroiditis with satisfactory results [1,13,14].

The purpose of this systematic review and meta-analysis was to evaluate the seroprevalence of toxoplasmosis and its relationship with different risk factors. The understanding of these relationships can aid in the analysis of the epidemiological pattern of disease among different population groups and the epidemiologic shift of *T. gondii* infection in Mexico.

Methods

Ethical Aspects

This study was approved by the Ethical Committee of the Health Sciences Center of the University of Guadalajara # C.I.100-2012.

Database search

Five databases were searched (Pub Med, Lilacs, Medline, Latindex and Google Scholar) from January to June of 2012. The following limits were applied: published January 1951 to 2012, the first case of human *T. gondii* infection was reported in an 11-month old girl from the Pediatric Hospital at Mexico City in 1950 [15], written in English or Spanish and undertaken in adults. The search terms were “infection with Toxoplasma”, “toxoplasmosis”, “epidemiology”, “risk factors”, “infection by T. gondii, Mexico” “anti-Toxoplasma antibodies” alone or combined.

Data collection

All retrieved studies were studied carefully by two investigators (GRML and BR). The extracted data included: year of publication, characteristics of the study population, location of the study, sample size, number of cases, diagnostic test and risk factors. Abstracts were included if considered acceptable, but were not included in the
meta-analysis for risk factors. Reference lists of full-text publications and textbooks were also examined to identify studies not retrieved by the original search.

**Data analysis**

The crude prevalence data and the weighted prevalence were calculated for each study (Table 1) [16-59]. Seven different types of diagnostic tests were identified during the literature search. Table 2 summarizes their main characteristics, sensitivity and specificity, and their timeline of employment in Mexico. Study groups were also stratified according to categories alone (Table 3) or by combining the risk group and diagnostic test used in each study [60-66] (Table 4).

The study groups were divided into: 1) Individuals with risk factors were designated as high risk groups that included: women who had had abortions, immunocompromised patients with AIDS or HIV, leprous people, patients with neurological disorders, pet-cat, owners and slaughterhouse workers; 2) Individuals without risks factors were designated in low risk groups: blood donors, patients with neurological disorders, pet-cat, owners and slaughterhouse workers; 3) Individuals with neurological disorders, pet-cat, owners and slaughterhouse workers; 2) Individuals without risks factors were designated in low risk groups: blood donors, patients with neurological disorders, pet-cat, owners and slaughterhouse workers.

**Statistical methods**

**Crude prevalence**

The crude prevalence of each study group was estimated to assess the amount of affection by the disease expressed in percentage of positives cases in relation to all cases analyzed. It was calculated as the number of positive cases divided by the sample size of the cohort in each study group.

**Weighted population prevalence (WP)**

The assessment of the prevalence of *T. gondii* of the different study groups was estimated by using the weighed population prevalence, given that not all the studies included the same number of individuals. This strategy restricts the bias that may impose the heterogeneous nature of the reports, and has proven to be valid when combining a number of studies with inherent heterogeneity in sample size and effects [67].

Each crude prevalence was multiplied by a "weight", which was proportional to the number of subjects included in the sample, i.e., in large samples, the prevalence found outweighs that of small samples. This prevalence is obtained by summing the product of the prevalence for its "weight" of the sum of the "weights". This estimate is more accurate than the overall crude prevalence to estimate the true prevalence of a cumulative set of groups. The formula to calculate the population prevalence (weighed prevalence, WP) of *T. gondii* in all groups or subgroups, included in this meta-analysis was \( P = \sum (p_i)(1/v_i)/\sum 1/v_i \) as explained by Borenstein et al. [68].

**Definitions**

- \( i \) = Number of studies in each group
- \( N_i = \) Total number of cases in each study, \( A_i = \) Number of positive cases from each study, \( (N_i-A_i) \) is the number of negative cases in each study. The risk of infection as a proportion in each study \( (p_i) \) was calculated as \( A_i/N_i \). The variance of each study \( (v_i) \) was calculated as \( A_i(N_i-A_i)/N_i^3 \). The standard error \( (SE) \) of each study was estimated as \( 1/\sqrt{v_i} \).
- The total population variance \( (V) \) was calculated as \( 1/\sum v_i \). The standard error of the population was calculated as \( SE = \sqrt{V} \). The confidence interval \( (C.I.95\%) \) for the population prevalence was obtained by \( P \pm 1.96 SE \) (upper limit) and \( P - 1.96 EE \) lower limit. The probability that the prevalence could be different from zero was calculated with a Z test, \( Z = P/SE \).

**Forest plot**

A Forest Plot chart was built in order to provide a comprehensive analysis of the studies included in the meta-analysis according to its odd ratio and confidence interval (CI) [68].

**Linear regression analysis**

A bivariate linear regression analysis was conducted to determine the relationship between the seroprevalence of *Toxoplasma* infection over time. The regression coefficient was calculated by the equation \( y = a + b \times \), \( a = \) ordinate of origin, \( b = \) slope and the \( R^2 \) and \( p \) were obtained with the SPSS program (Version 18). The epidemiological behaviour of the prevalence of *Toxoplasma* infection was estimated by plotting the year of each publication date (independent variable) starting at year 1951 until 2012 versus the relative prevalence (dependent variable) reported in each study [68].

**Results**

From the five databases, a total of 45 publications were eligible that included 132 studies and 70,123 individuals, and 19,262 positive cases as shown in Table 1. As shown in Table 3, most of the studies were carried out in low risk groups, such as, the general population \( (n = 90 \) studies) followed by pregnant women \( (n = 12) \), with the least number of studies in blood donors \( (n = 4) \). In the high-risk groups, relatively fewer studies have been carried out; women with miscarriage \( (n = 3) \), immunocompromised patients \( (n = 7) \), mentally-ill patients \( (n = 4) \), other risk groups \( (n = 5) \) and patients with nonrelated comorbidity \( (n = 7) \). To the best of our knowledge, all the studies included in this meta-analysis had a cross-sectional design and were aimed to identify the prevalence of *T. gondii* antibodies in a cohort. No prospective or follow-up studies aimed to seek seroconversion or self-reported results were detected.
### Table 1 Publications included for meta-analysis with diagnostic methods and population characteristics

| Sequence | Year | First Author | State | Municipality | Test | Category | Number of cases | Positive cases | Prevalence (%) | Reference |
|----------|------|--------------|-------|--------------|------|----------|----------------|----------------|---------------|-----------|
| 1        | 1951 | Biagi F.     | Tamaulipas | Tampico      | STA  | GP       | 231            | 108            | 47            | [16]      |
| 2        | 1952 | Biagi F.     | México     | Mexico       | STA  | IC       | 155            | 58             | 37.4          | [49]      |
| 3        | 1952 | Bustos C.    | Veracruz   | Orizaba      | STA  | GP       | 86             | 31             | 51            | [17]      |
| 4        | 1953 | Biagi F.     | Campeche   | Escarcega    | STA  | GP       | 132            | 76             | 56.8          | [18]      |
| 5        | 1953 | Varela G.    | Estado de México | Toluca  | STA  | GP       | 500            | 81             | 16            | [19]      |
| 6        |       | Varela G.    | Mexico     | México       | STA  | CM       | 116            | 19             | 16            | [19]      |
| 7        |       | Varela G.    | Mexico     | México       | STA  | CM       | 47             | 7              | 14.8          | [19]      |
| 8        |       | Varela G.    | Mexico     | México       | STA  | CM       | 102            | 13             | 12.7          | [19]      |
| 9        |       | Varela G.    | Toluca     | Zoquiapan    | STA  | IC       | 107            | 13             | 14            | [19]      |
| 10       | 1954 | Gutierrez E.B.| México   | México       | CFT  | MI       | 58             | 14             | 24.14         | [53]      |
| 11       | 1955 | Varela G.    | Mexico     | México       | SF   | GP       | 60             | 16             | 26.7          | [20]      |
| 12       |       | Varela G.    | Michoacan  | N.E.         | SF   | GP       | 22             | 6              | 27.3          | [20]      |
| 13       |       | Varela G.    | Mexico     | México       | SF   | GP       | 104            | 39             | 37.5          | [20]      |
| 14       |       | Varela G.    | Oaxaca     | Oaxaca       | SF   | GP       | 276            | 96             | 34.8          | [20]      |
| 15       |       | Varela G.    | Tamaulipas | N.E.         | SF   | GP       | 230            | 90             | 39            | [20]      |
| 16       |       | Varela G.    | Yucatan    | N.E.         | SF   | GP       | 17             | 11             | 64.7          | [20]      |
| 17       |       | Varela G.    | Distrito federal | Mexico      | SF   | MI       | 91             | 54             | 59            | [20]      |
| 18       |       | Varela G.    | Puebla     | N.E.         | SF   | GP       | 44             | 41             | 93.2          | [20]      |
| 19       | 1957 | Biagi F.     | México     | Ixtapalapa, D.F. | STA  | GP       | 272            | 37             | 13.6          | [21]      |
| 20       | 1961 | Varela G.    | Baja, California | Mexicali | SF   | GP       | 73             | 26             | 35.9          | [22]      |
| 21       |       | Varela G.    | Chihuahua  | Chihuahua    | SF   | GP       | 12             | 3              | 25            | [22]      |
| 22       |       | Varela G.    | México     | Distrito Federal | SF   | GP       | 2,463         | 783            | 31.8          | [22]      |
| 23       |       | Varela G.    | Hidalgo    | Apan         | SF   | GP       | 409            | 117            | 28.6          | [22]      |
| 24       |       | Varela G.    | Estado de México | Toluca       | SF   | GP       | 64             | 15             | 23.4          | [22]      |
| 25       |       | Varela G.    | Michoacan  | Morelia      | SF   | GP       | 35             | 11             | 31.42         | [22]      |
| 26       |       | Varela G.    | Morelos    | Various      | SF   | GP       | 208            | 54             | 25.96         | [22]      |
| 27       |       | Varela G.    | Nayarit    | Tepic        | SF   | GP       | 112            | 25             | 22.3          | [22]      |
| 28       |       | Varela G.    | Oaxaca     | Oaxaca and Tuxtepec | SF   | GP       | 546            | 107            | 19.59         | [22]      |
| 29       |       | Varela G.    | Puebla     | Puebla       | SF   | GP       | 170            | 61             | 35.9          | [22]      |
| 30       |       | Varela G.    | Queretaro  | Various      | SF   | GP       | 90             | 33             | 36.66         | [22]      |
| 31       |       | Varela G.    | Sinaloa   | Culiacan     | SF   | GP       | 311            | 109            | 35            | [22]      |
| 32       |       | Varela G.    | Sinaloa   | Mazatlan     | SF   | GP       | 100            | 16             | 16            | [22]      |
| 33       |       | Varela G.    | Tabasco   | Macuspana    | SF   | GP       | 108            | 38             | 35.2          | [22]      |
| 34       |       | Varela G.    | Tamaulipas | Ciudad Victoria | SF   | GP       | 220            | 39             | 17.7          | [22]      |
| 35       |       | Varela G.    | Tamaulipas | Nuevo Laredo | SF   | GP       | 100            | 28             | 28            | [22]      |
| 36       |       | Varela G.    | Tlaxcala   | Tlaxcala     | SF   | GP       | 594            | 144            | 24.2          | [22]      |
| 37       |       | Varela G.    | Veracruz   | Boca del Rio | SF   | GP       | 93             | 36             | 38.7          | [22]      |
| 38       |       | Varela G.    | Veracruz   | Soconusco    | SF   | GP       | 121            | 39             | 32.2          | [22]      |
| 39       |       | Varela G.    | Veracruz   | Veracruz     | SF   | GP       | 125            | 30             | 24            | [22]      |
| 40       |       | Varela G.    | Yucatan    | Merida       | SF   | GP       | 17             | 11             | 64.7          | [22]      |
| Year | Author(s) | Region | Method | Population Characteristics | Cases | Controls | Prevalence | Reference |
|------|-----------|--------|--------|-----------------------------|-------|---------|------------|-----------|
| 1962 | Carrillo C. | México | SF BD | 232 73 | 31.4 | [46] |
| 1965 | Espinosa de los Reyes VM | México | SF PW | 329 112 | 34 | [37] |
| 1966 | Roch E. | Distrito Federal | México | SF MW | 2,320 815 | 35.13 | [44] |
| 1966 | Roch E. | Mexico | All States | SF GP | 14,869 4,411 | 30 | [23] |
| 1972 | Goldsmith RS. | Oaxaca | Puerto Escondido | IHA GP | 159 2 | 1.26 | [24] |
| 1972 | Goldsmith RS. | Oaxaca | Mixteca Alta | IHA GP | 114 0 | 0 | [24] |
| 1972 | Goldsmith RS. | Oaxaca | Ixtlan | IHA GP | 48 2 | 4.2 | [24] |
| 1972 | Goldsmith RS. | Oaxaca | Región del Valle | IHA GP | 150 5 | 3.3 | [24] |
| 1972 | Goldsmith RS. | Oaxaca | Tehuantepec | IHA GP | 137 18 | 13 | [24] |
| 1974 | Biagi F. | México | FL WP | 367 73 | 19.9 | [35] |
| 1974 | Fernandez Terrano | Tabasco | Región de los Ríos | IIF-G WP | 125 75 | 60 | [36] |
| 1986 | Galvan-Ramirez ML | Jalisco | IIF-G GP | 807 25 | 3.1 | [25] |
| 1991 | Velasco-Castrejon O | Mexico | All states | IIF-G GP | 29,279 9,371 | 32 | [27] |
| 1995 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G PW | 350 122 | 34.9 | [39] |
| 1997 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G MW | 105 48 | 44.9 | [39] |
| 1997 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G PW | 50 13 | 26.0 | [39] |
| 1999 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G IC | 39 27 | 69.2 | [50] |
| 2000 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G IC | 53 19 | 35.8 | [50] |
| 2000 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G IC | 30 14 | 47 | [38] |
| 2000 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G PW | 30 13 | 43 | [38] |
| 2004 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G MW | 60 17 | 28.3 | [38] |
| 2005 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G PW | 139 104 | 29 | [5] |
| 2006 | Alvarado-Esquivel C | Durango | Guadalajara | ELISA-G PW | 343 21 | 6.1 | [41] |
| 2006 | Alvarado-Esquivel C | Durango | Durango | ELISA-G BD | 432 32 | 7.4 | [48] |
| 2008 | Alvarado-Esquivel C | Durango | Durango | ELISA-G ORG | 90 19 | 21.1 | [58] |
| 2008 | Alvarado-Esquivel C | Durango | Durango | ELISA-G ORG | 83 7 | 8.4 | [58] |
| 2008 | Alvarado-Esquivel C | Durango | Durango | ELISA-G GP | 187 67 | 35.8 | [30] |
| 2008 | Alvarado-Esquivel C | Durango | Durango | ELISA-G GP | 121 20 | 16.5 | [30] |
| 2008 | Alvarado-Esquivel C | Durango | Durango | ELISA-G GP | 155 23 | 14.8 | [30] |
| 2009 | Galvan-Ramirez ML | Jalisco | Guadalajara | ELISA-G ORG | 145 104 | 72 | [6] |
| 2009 | Alvarado-Esquivel C | Durango | Guadalajara | ELISA-G PG | 439 36 | 8.2 | [42] |
| 2010 | Cañedo-Solares I | Distrito Federal | Mexico | ELISA-G PG | 100 30 | 30 | [43] |
| 2010 | Alvarado-Esquivel C | Durango | Durango | ELISA-G GP | 248 22 | 8 | [31] |
| 2010 | Alvarado-Esquivel C | Durango | Durango | ELISA-G GP | 61 4 | 6.6 | [56] |
Table 1 Publications included for meta-analysis with diagnostic methods and population characteristics (Continued)

| Publication Date | Authors | Location | Type | Diagnostic Method | Population | Sensitivity | Specificity | Timeline | References |
|------------------|---------|----------|------|-------------------|------------|-------------|------------|----------|------------|
| 2012             | Alvarado-Esquivel C. | Durango | Durango ELISA-G | CM         | 266 14 5.3 | [33]        |
| 2012             | Alvarado-Esquivel C. | Durango | Durango ELISA-G | GP         | 156 35 22.4 | [34]        |
| Total            |          |          |      |                   |            | 70,123 19,262 | [33,34]   |

Skin test antigen (toxoplasmin) (STA); Complement Fixation Test (CF); Latex Flocculation Test (LF); Sabin & Feldman (SF); Indirect Haemagglutination Test (IHA); Enzyme-linked immunosorbent assay and type of antibody detected (ELISA-G), Indirect Immunofluorescence assay and type of antibody detected (IFI-G); General Population (GP); Pregnant Women (PW); Blood Donors (BD); Patients with Comorbidity (CM); Immuno compromised patients (IC); Women with Miscarriages (MW); Mentally-ill patients (MI); Other risk groups (ORG).

Table 2 Diagnostic methods

| Diagnostic test                          | Fundament                                                                 | Sensitivity | Specificity | Timeline | References |
|------------------------------------------|---------------------------------------------------------------------------|-------------|-------------|----------|------------|
| Skin test antigen (STA Type IV cell-mediated hypersensitivity reaction against the T. gondii antigen.) | 80% 70%                                                  | 1950-1951   | [16-19,21,49] |
| Sabin and Feldman Dye Test (SF)          | The gold standard. A dye test in which the serum antibodies alter the staining pattern of the T. gondii tachyzoites. | 96% 98%     | 1955-2005   | [20,22,23,37,44,46] |
| Complement Fixation Test (CF)            | Antigen-antibody complexes are formed and detected by using a standard system with hemolisin and complement | 97.1% 64.5% | 1954-1982   | [53]     |
| Látex Flocculation Test (LF)             | This test uses latex particles for antigen-antibody flocculation.        | No reported | 1974        | [35]     |
| Indirect Fluorescent Antibody Test (IFI) | Tachyzoites are fixed on a slide and exposed to test serum, then washed and exposed to a standard antibody labeled with fluorescent dye. | 95% 96% | 1986 to date | [5,25,27,28,36,38,54] |
| Indirect Haemagglutination Test (IHA)    | This test uses sheep red cells exposed to tannic acid and then to the soluble antigen fixed at 37 °C. | 95% 96%     | 1972 to 1989 | [24,26] |
| Enzyme-linked immunosorbent assay (ELISA) | The ELISA detects T. gondii immunoglobulin IgG e IgM in serum and other body fluids with antibodies marked with peroxidase and fosfatase enzymes | 100% 98.4%  | 1995 to date | [6,7,29-34,39-43,47,48,50-52,55,56] |
Meta-analysis in low risk groups

**General population**
Most of the studies were carried out in low risk groups such as the general population (90 studies) that gave a total of 61,536 people tested for *T. gondii* infection. The WP was 20.26% (CI95% 18.78% – 19.36%) with a variance of 0.0002% and a standard error of 0.1463%, Z = 130.391 and p <0.001 (Table 3).

**Pregnant women**
In this study group, 12 publications included 2,595 pregnant women. The WP was 15.62% (CI95% 14.30% – 16.93%), with a variance of 0.0045% and standard error of 0.67%, Z = 23.313 and p <0.001 (Table 3).

**Blood donors**
In 4 studies, a total of 1123 blood donors were tested. The WP was 17.03% (CI95% 15.03% – 19.03%) with a variance of 0.00104% and standard error of 1.0213%, Z = 16.679 and p <0.001 (Table 3).

**Patients with comorbidity**
In 689 cases from seven studies, a WP of 12.27% (CI95% 9.83 – 14.72) was found with a variance of 0.0155%, standard error of 1.2463%, Z = 9.85 and p <0.001 (Table 3).

Meta-analysis in high-risk groups

**Women with miscarriages**
In 3 studies, 2595 women were tested. The WP was 35.96% (CI 95% 34.10% – 37.83%) with a variance of 0.0091% and standard error of 0.9532%, Z = 37.73 and p <0.001 (Table 3).

**Immunocompromised patients**
In this study group, 627 patients from seven studies were included. The WP was 20.20% (CI95% 17.35%- 23.05%) Table 3 Crude and weighted *Toxoplasma* infection prevalence in low and high risk groups of Mexican population

| Population studied | Number of studies | Number of cases | Positive cases | A/Nx100 Crude prevalence (%) | Weighed prevalence (%) | CI 95% Lower-upper limit (%) | References |
|--------------------|------------------|----------------|---------------|-----------------------------|------------------------|-----------------------------|------------|
| Low Risk Groups    |                  |                |               |                             |                        |                             |            |
| General population | 90               | 61536          | 16855         | 27.39                       | 20.26                  | 18.78-19.36                 | [16-24,34,51,52,55,56,58,59] |
| Pregnant Women     | 12               | 2595           | 573           | 22.08                       | 15.62                  | 14.30-16.93                 | [35-43]    |
| Blood Donors       | 4                | 1123           | 278           | 24.76                       | 17.035                 | 15.03-19.03                 | [5,46-48]  |
| Patients with comorbidity | 7 | 689   | 88            | 12.77                       | 12.27                  | 9.83-14.72                 | [19,51,59] |
| High Risk Groups   |                  |                |               |                             |                        |                             |            |
| Women with miscarriages | 3       | 2525          | 910           | 36.03                       | 35.96                  | 34.1-37.83                  | [39,44,45] |
| Immunocompromised patients | 7 | 627   | 179           | 28.54                       | 20.2                   | 17.35-23.05                 | [19,47,49-52] |
| Mentally-ill patients | 4       | 527           | 203           | 38.52                       | 37.24                  | 33.24-41.26                 | [20,53-55] |
| Other risk groups  | 5                | 501            | 176           | 35.13                       | 21.88                  | 19.0-24.76                  | [6,7,57,58] |
| Total              | 132              | 70,123         | 19,262        |                             |                        |                             |            |

Complement Fixation (CF), Skin test antigen toxoplasmin (STA), Latex Floculation (LF), Sabin and Feldman (SF), Indirect Hemaglutination (IHA), Indirect Fluorescence (IFI), Enzyme-linked immunosorbet assay (ELISA). All prevalences calculated by meta-analysis were statistically significant (p < 0.001).
with a variance of 0.0211% and standard error of 1.45%, $Z = 13.90$ and $p <0.0001$ (Table 3).

**Mentally-ill patients**

A total of 527 mentally-ill patients were included from four studies. The WP was 37.24% (CI95% 33.24% - 41.26%) with a variance of 0.0994% and standard error of 3.15%, $Z = 11.43$ and $p <0.001$ (Table 3).

**Other risk groups**

In 501 cases from five studies, a WP of 21.88% (CI95% 19.00% - 24.76%) was found with a variance of 0.0215%, standard error of 1.46%, $Z = 14.91$ and $p <0.001$ (Table 3).

**Weighted prevalence by diagnostic test and risk factors**

In order to determine, if the prevalence of *T. gondii* was based on the diagnostic test, the study groups were adjusted by diagnostic test and risk factors reported. Only the studies that used the SF assay and ELISA showed a correlation between the low and high risk. Interestingly, the rest of the diagnostic tests showed a lower prevalence, although it is noteworthy to mention that the difference may be due to the number of cases in the risk group categories (Table 3).

**Epidemiological transition of Toxoplasma infection in Mexico**

Figure 1 illustrates the Forest Plot analysis of the WP (CI95%) of each study included in this meta-analysis. The linear regression analysis of *Toxoplasma* infection in the Mexican population over a time span of 60 years showed a downward trend of 0.1%/year that represents an overall 5.8% reduction of infection ($R^2 = 0.0354$ and $F (1) =4.802$, $p > 0.05$) that was not statistically significant (Figure 2).

**Discussion**

The questions that led us to achieve this study were if Mexico had a significant prevalence of toxoplasmosis, and if there have been changes in the epidemiology of this disease from 1951 to date. Five databases were searched, and 132 studies were selected involving 70,123 individuals and 19,262 positive cases.

This study showed that the WP of toxoplasmosis in Mexico was 20.26%, which is relatively low compared to the mean prevalence of 32% reported in 1991 [27]. This can be explained if we note that variations between methodologies can result in heterogeneity of the estimations. However, despite this situation, at least 20.26% of Mexicans may have been exposed to toxoplasmosis.

Between 1951 and 1958, the STA was an appropriate test since, at that time, it was a rapid and sensitive assay for epidemiological studies. It did not give cross-reactions with other parasites, but it did make a fair amount of false-negatives in mild infections. This was one of its disadvantages when used for a survey in the general population in Tamaulipas, Campeche and Mexico City (1953). The WP was 21.31% in 11 study groups with 1846 cases [16-20]. Since only one study was performed by the FL test with 367 individuals, and another study included 58 cases tested by fixation complement, we were not able to compare these results against the SF or IFI assays.

The SF test was used in epidemiological studies carried out between 1961 and 1966. The CP and WP was 30% and 35.12%, respectively [23]. The advantage of this test
is that it is a gold standard, and it is highly sensitive, although the disadvantage is that it requires live parasites. The global prevalence during that time was 14.92%, which is closer to the prevalence of 8.26% aforementioned. In the same period, the IFI test was introduced and was then used in the largest survey carried out in Mexico (1992) with 29,279 people with a mean prevalence of 32.0% [27]. The meta-analysis of all tests performed with IFI was 29.32%, because the majority of studies have used this method (31,412 cases).

In the 80s, the ELISA methods were introduced with higher sensitivity and specificity that reduced the number of cross-reactions. Interestingly, the WP was lower, ranging from 8.92% to 17.66%, which may have been caused by the lower number of cases, (8256 cases), less than one-third of the studies, when compared to the 26,751 cases tested with SF and the 30,485 cases with IFI.

The general population involved 61,536 cases with a WP of 20.26%, while the mean prevalence was reported as 32% in 1991 [27]. This discrepancy may be caused by the differences in the diagnostic methods that are then adjusted when the weighted prevalence was estimated [27].

Pregnant women presented a WP of 15.62% with an upper limit of 16.93% that is closer to the general population prevalence (20.26%), which is reasonable since these women did not have obstetric complications. These values were lower compared to 45.8% and 30.5%, respectively for specific IgG antibodies detected by the Sabin-Feldman dye test in two separate studies among pregnant women [69], however, our results were higher than 0.6% among pregnant women in Norway [70].

In the four studies performed in blood donors, the WP was 17.03% among 1123 cases. This prevalence is also closer to the general population prevalence, despite that each one of them was carried out with different diagnostic tests (one with SF [46], one not reported [47], one with IFAT [5] and one with ELISA, respectively [48]).

Regarding the blood donors group, this group has a lower WP when compared to the general population. Transfusion Medicine guidelines have pronounced that donated blood should be screened for toxoplasmosis, because of the potential risk for blood receptors receiving transfusions from subjects in the acute phase of infection. Therefore, testing of toxoplasmosis in blood donations should be mandatory in the country [5,46-48].

Three studies performed in Mexico were in women with miscarriages having primary infection during pregnancy. There were clear differences between the WP of pregnant women 15.62% whereas those with miscarriages had 35.96% (p <0.05). These results are concordant with other studies that have shown an association between high prevalence of miscarriages and *Toxoplasma* infection [39,44,45].

Another risk group was the immunocompromised patients. Among 627 cases, the WP of 20.2% was the
same as in the general population. One explanation is that the patients were diagnosed by different methods, and two studies performed in Durango had the lowest prevalence [47,49-52].

The highest WP was 37.24% in the mentally-ill patients, at least 18.27% higher than the general population [55]. Several authors have reported a high prevalence of Toxoplasma antibodies in patients with schizophrenia, although other factors such as genetic may be present in the schizophrenia. Different reports have shown that toxoplasmosis is somehow associated with cases of schizophrenia. This finding justifies the need to examine the relationship between toxoplasmosis and schizophrenia with pre-clinical and clinical trials aimed to improve prevention and treatment programs in patients with psychiatric illness [71,72]. On the other hand, a meta-analysis of latent Toxoplasma gondii infection in immunocompetent hosts and cryptogenic epilepsy showed a strong association between seroprevalence rates for toxoplasmosis and prevalence rates of epilepsy. If an etiological connection can be proven, it would have implications for the implementation of prevention and treatment strategies for Toxoplasma disease [73].

Cat owners and slaughterhouse workers presented both a CP and WP of 21.88% each. This may be because only five studies with 501 individuals with this attribute were analyzed. Regarding patients with nonrelated comorbidity, WP was 12.28%, lower than in the general population. Three groups were studied with STA and four more from Durango had the lowest prevalence in the country, which may show that their comorbidity was not related to the risk of infection.

Another important factor is the difference in the prevalence of T. gondii infections due to the sensitivity and specificity of diagnostic tests, since there are several methods to identify and evaluate antibodies in individuals who were infected by the parasite. Over time, at least four different diagnostic assays have been used worldwide that range from the lowest specificity and sensitivity like the STA progressing on to the SF Dye Test and other similar tests up to the improved ELISA (Table 2) [7,74].

In regards to the analysis of the study groups adjusted by risk factors (with or without) and diagnostic test, we found that only those tested by ELISA showed a WP of 17.66% in the risk factor groups against a WP of 8.92% in the groups without risk factors. However, with the other methods, both crude and weighted prevalence were reduced; however, the number of studied individuals was higher. This analysis demonstrates that the prevalence varies according to the diagnostic method and by the number of individuals tested in each study group (Figure 2).

The epidemiological behavior of Toxoplasma infection showed a negative slope of −0.1%/year, which represented an accumulated decrement of nearly 6% in the prevalence of infection in Mexico after 60 years. This may suggest that we have not paid enough attention to T. gondii infection as a public health problem though it tends to decrease. However, another key issue is that if the studies carried out in the first 10 years had been tested with ELISA then the decrement would have been even lower (Figure 2).

In this study, stratification of studies based on molecular assays was not feasible because none was reported. However, genotyping has been reported in other Latin American populations, such as Colombia where a virulent strain (LD100 of 10 tachyzoites) was identified as clonal type 1 (CIBMUQ/HDC) [75]. Additionally, in another study, the GRA6 type I/III profile was the most frequent among asymptomatic cases (68/148, 45.9%) and in severe multi visceral cases (2/4, 50%). Furthermore, GRA6 type II, was found in one case of congenital toxoplasmosis, one case of severe multi visceral infection, one case of ocular infection, and in five cases (5/148,3.4%) of asymptomatic patients [76]. Further studies based on genetic-based diagnostic assays will be relevant in the future, since Toxoplasma gondii isolates from Latin America have mixed/recombinant genetic structure.

A 6% decrement in the prevalence of Toxoplasma infection after 60 years of studies was detected. This decrement is quite low after a relatively long period, contrary to what has been reported in the United States, with a 14% decrement in only one decade [77]. Therefore, our data warrants that researchers must pay more attention to this disease and to communicate to the medical community the need of improvement of the prevention strategies, together with effective diagnostic testing and management of patients in high risk of infection such as immunocompromised patients and pregnant women.

Further research is still required to understand and clarify the role of T. gondii in its diverse routes of transmission, as well as to design better control measures that focus on minimizing the risk of infection. The purpose of such studies should be to aid in the monitoring of changes in the epidemiology of T. gondii infection, and to strengthen educational efforts in order to avoid the transmission of infection in populations that cannot be controlled by drugs alone.

Implications for research
A crucial factor is the difference in the prevalence of T. gondii infections due to the sensitivity and specificity of the diagnostic tests, since there are several methods to identify and evaluate antibodies in individuals who were infected by the parasite. At least four different diagnostic assays have been used in this study, that range from the lowest specificity and sensitivity like the CF, progressing
on to the SF dye test and other similar tests up to the improved ELISA.

Conclusion
In conclusion, to the best of our knowledge, this is the first study that provides a comprehensive view of the epidemiological situation on the prevalence of *T. gondii* infection among the adult Mexican population. It provides not only epidemiological evidence relevant to Mexico, but to other countries in the Americas and worldwide as well, where it has been documented that *T. gondii* prevalence is shifting, related to regional climate changes among other factors. In this study, the major risk groups with Toxoplasma infection were women with miscarriages, immunocompromised patients, mentally-ill patients and other risk groups. Noteworthy was the psychiatric patients group, since *T. gondii* can cause serious damage to the central nervous system.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
MLG and SR wrote the manuscript, CC and RB database information search.

Received: 10 August 2012 Accepted: 27 October 2012
Publish: 26 November 2012

References
1. Galván-Ramírez ML, Mondragón-Flores R: Toxoplasmosis humana. Guadalajara JAL Mexico: Editorial Cuellar; 2001.
2. Galván-Ramírez ML, Madriz A, Rico C, Luna-Pastén H, Rodríguez-Pérez L, Rincón-Sánchez AR, Franco R, Salazar-Montes A, Correa D: Frequency of Toxoplasma gondii in pork meat in Coxtotlán, Jalisco, Mexico. J Food Prot 2010, 73:1121–1123.
3. Galván-Ramírez ML, Castillo-de-León Y, Espinoza-OLiva M, Borja-ramos MC, Rodríguez-Pérez LR, Bernal Redondo R, Caldeo-Solares I, Espinoza López L, Correa D: Acute infection of Toxoplasma gondii and cytomegalovirus reactivation in a pediatric patient receiving liver transplant. Transpl Infect Dis 2006, 8:233–236.
4. Galván-Ramírez ML, Rincon A, Bernal R: Diagnostic of opportunistic parasites in liver transplantation. In Parasitology research trends. Volume 1. 1st edition. Edited by de Bruyn O, Stephane P. New York: Nova; 2010:210–254.
5. Galván-Ramírez ML, Covarrubias K, Rodriguez R, Troyo R, Alfaro N, Correa D: Toxoplasma gondii antibodies in Mexican blood donors. Transfusion 2005, 45:281–282.
6. Galván-Ramírez ML, Orozco C, Mancill J: Seroepidemiology of Toxoplasma gondii in workers of slaughterhouse in Zapopan, Jalisco (abstract). Int J Infect Dis 2008, 12:584.
7. Galván-Ramírez ML, Sánchez G, Vielma M, Soto Mancha JL: Presence of anti-Toxoplasma antibodies in humans and their cats the urban zone of Guadalajara. Rev Soc Bras Med Trop 1999, 32:483–488.
8. Patz J, Graczyk T, Geller N, Vittor ATY: Effects of environmental change on emerging parasitic diseases. Int J Parasitol 2000, 30:1395–1405.
9. Meereburg B, Klijistra A: Changing climate—changing pathogens: Toxoplasma gondii in North-Western Europe. Parasitol Res 2009, 105:17–24.
10. Tenter AM, Hecker Roth AR, Weiss LM: Toxoplasma gondii: from animals to humans. Int J Parasitol 2000, 30:1217–1258.
11. el-On J, Peiser J: Toxoplasmosis and toxoplasmosis. Haarhush 2003, 142:48–55.
12. Galván-Ramírez ML, Troyo-Sanromán R, Roman S, Bernal-Redondo R, Vázquez-Castellanos JL: Prevalence of toxoplasma infection in Mexican newborns and children: a systematic review from 1954 to 2009. ORIN Pediatr 2012, 2012:201216, doi:10.5402/2012/201216.
13. Guex-Crosier Y: Update on the treatment of ocular toxoplasmosis. Int J Med Sci 2009, 6:140–142.
14. Baláskas K, Vaudaux J, Botillót-Blanco N, Guex-Crosier Y: Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit 2012, 18:96–302.
15. Palomino F, Soto R, Villegas L: Un caso de toxoplasmosis. Bol Hosp Infant Mex 1950, 1:24–39.
16. Bofi G: Cutireacciones con Toxoplasmosis en Tampico. Rev Med Hosp Gen Mex 1951, 14:191.
17. Bustos C, Aguilar C, López V: Investigación sobre toxoplasmosis en la Región de Orizaba, Ver. Boletín de Salubridad y Higiene 1952, 81–18.
18. Bofi F: Intradermal tubercul and toxoplasmin reactions in Escarcega, Camp. transmission of toxoplasmosis, Med Rev Mex 1953, 33:268–272.
19. Varela G, Martínez E, Treviño A: Toxoplasmosis in the Republica Mexicana. Rev Inst Salud Enfer Trop 1953, 13:217–224.
20. Varela G, Roch E, Vázquez A: Virulencia, culture, polysaccharides, toxins and the dye test, studies with a strain of Toxoplasma gondii. Rev Inst Salud Enferm Trop 1955, 15:73–80.
21. Bofi F, Almeny J: Intraderma-reacciones con Toxoplasmina en Ixtapala, D.F. Bol Med Hosp Inf Mex 1957, 14:125–128.
22. Varela G, Roch E, Zavala J: Estudios sobre toxoplasmosis en México. Salud Pub Med Mex 1961, 3:451–454.
23. Roch E, Varela G: Diversos aspectos de la investigación sobre toxoplasmosis en México. Resultados obtenidos en 29,883 reacciones de Sabiny y Feldman efectuadas de 1953 a 1965. Rev Inst Salud Publica Mex 1968, 28:31–49.
24. Goldsmith RS, R, Reyes-Gonzalez G, Cedeno MA, Ferreita J: Seroepidemiologic studies in Oaxaca, Mexico. Bull Pan Am Health 1972, 83:59–52.
25. Galván M, Ganzón M: Estudio serológico en niños con Toxoplasmosis. Rev Latinoam Microbiol 1989, 31:267–270.
26. Goldsmith R, Kagan I, Zárate R, Reyes-Gonzalez MA, Cedeno-Ferreira J: Low Toxoplasma antibody prevalence in serologic surveys of humans in southern Mexico. Arch Invest Med Mex 1992, 73:653–73.
27. Velasco-Castrejón O, Salavatera-Izaba B, Valdespino JL, Sedano-Lara AM, Galindo-Virgen S, Magos C, Láausa A, Tapia-Conyer R, Gutiérrez G, Sepúlveda J: Seroepidemiología de la Toxoplasmosis en México. Salud Publica Mex 1992, 34:222–229.
28. Galván-Ramírez M, Rodríguez R, Ledeuna S, Sifuentes LM, Armenta AS, Bayardo D, Ramírez BJ, Troyo Sanromán R: Seroepidemiology of toxoplasmosis in high-school students in the metropolitan area of Guadalajara, Jalisco, Mexico. Sci Med (Porto Alegre) 2010, 20:1–15.
29. Kelso Santos E, Torres E, Cárdenas del Toro C, Salinas MC, Medina CE: Seropositividad a Toxoplasma gondii en adultos del área metropolitana de Monterrey: Reporte preliminar. Med Univer 2000, 2:77–81.
30. Avarado-ESquivel C, Cruz-Magalán de HM, ESquivel-Cruz R, Estrada-Martínez S, Rivas-González M, Liesenfeld O, Martínez-García SA, Ramírez E, Torres-Castrorena A, Castañeda A, Dubey JP: Seroepidemiology of Toxoplasma gondii infection in human adults from three rural communities in Durango State, Mexico. J Parasitol 2008, 94:811–816.
31. Avarado-ESquivel C, Rojas-Rivera A, Estrada-Martínez S, Sifuentes-Alvarez A, Liesenfeld O, García-López CR, Dubey JP: Seroepidemiology of Toxoplasma gondii infection in a Mennonite community in Durango State, Mexico. J Parasitol 2010, 96:941–945.
32. Avarado-ESquivel C, Estrada-Martínez S, Pizarro-Villalobos H, Arce-Quiliones M, Liesenfeld O, Dubey JP: Seroepidemiology of Toxoplasma gondii infection in general population in a northern Mexican city. J Parasitol 2011, 97:40–43.
33. Avarado-ESquivel C, Torres-Castrorena A, Liesenfeld O, Estrada-Martínez S, Litnina-Ariana ID: High seroprevalence of Toxoplasma gondii infection in a subset of Mexican patients with work accidents and low socioeconomic status. Parasit Vectors 2012, 5:133.
